Get the Stockscreener App
2.29
2.97%
-0.07
Traws Pharma Inc stock is traded at $2.29, with a volume of 92,675.
It is down -2.97% in the last 24 hours and up +5.53% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
See More
Previous Close:
$2.36
Open:
$2.35
24h Volume:
92,675
Relative Volume:
0.30
Market Cap:
$18.30M
Revenue:
$2.90M
Net Income/Loss:
$87.91M
P/E Ratio:
0.1467
EPS:
15.6103
Net Cash Flow:
$-26.93M
1W Performance:
-15.19%
1M Performance:
+5.53%
6M Performance:
+54.73%
1Y Performance:
-54.60%
1-Day Range:
$2.27
$2.3999
1-Week Range:
$2.02
$2.76
52-Week Range:
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.29 | 18.86M | 2.90M | 87.91M | -26.93M | 15.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | H.C. Wainwright | Buy |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
Traws Pharma (NASDAQ:TRAW) Upgraded at Zacks Research - Defense World
Traws Pharma (NASDAQ:TRAW) Cut to “Sell” at Wall Street Zen - Defense World
HC Wainwright Estimates Traws Pharma Q4 Earnings - Defense World
Can Traws Pharma Inc. (0T20) stock sustain institutional flowsTrade Risk Assessment & Consistent Growth Equity Picks - Newser
What earnings margins imply for Traws Pharma Inc. (0T20) stock2025 Pullback Review & Scalable Portfolio Growth Methods - Newser
HC Wainwright Begins Coverage on Traws Pharma (NASDAQ:TRAW) - Defense World
Is Traws Pharma Inc. stock trading near support levelsTrade Performance Summary & AI Powered Buy/Sell Recommendations - Newser
How Traws Pharma Inc. (0T20) stock behaves under inflation pressureJuly 2025 Outlook & Precise Trade Entry Recommendations - Newser
Will Traws Pharma Inc. (0T20) stock benefit from sector leadership2025 Pullback Review & AI Forecasted Entry/Exit Points - Newser
Why ETFs are accumulating Traws Pharma Inc. (0T20) stockQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Is Traws Pharma Inc. (0T20) stock positioned for secular growthWeekly Loss Report & Weekly High Return Stock Forecasts - Newser
Is Traws Pharma Inc. (0T20) stock prepared for digital transition2025 Market WrapUp & Stepwise Trade Signal Guides - Newser
HC Wainwright & Co. Initiates Coverage of Traws Pharma (TRAW) with Buy Recommendation - Nasdaq
This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Traws Pharma (TRAW) Receives Buy Rating from HC Wainwright & Co. - GuruFocus
Is Traws Pharma Inc. stock a safe buy before earnings2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
Will Traws Pharma Inc. (0T20) stock recover faster than industry - Newser
Traws Pharma shareholders approve incentive plan changes and elect directors - Investing.com Nigeria
Traws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir - MSN
[Form 4] Traws Pharma, Inc. Insider Trading Activity - Stock Titan
Traws Pharma Inc (TRAW) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Traws Pharma’s TRX-100 Study: A Potential Game-Changer in Pharmacokinetics - MSN
Is Traws Pharma Inc. stock a defensive play in 2025Rate Cut & Consistent Return Strategy Ideas - newser.com
Is Traws Pharma Inc. (0T20) stock testing key supportCEO Change & Safe Capital Investment Plans - newser.com
Why Traws Pharma Inc. (0T20) stock could be next leaderMarket Activity Summary & Fast Moving Market Watchlists - newser.com
How Traws Pharma Inc. stock reacts to inflationary pressuresLong Setup & Consistent Growth Stock Picks - newser.com
Is Traws Pharma Inc. stock a contrarian buyCEO Change & Consistent Profit Trade Alerts - newser.com
Is a relief rally coming for Traws Pharma Inc. holdersRate Hike & Safe Capital Growth Trade Ideas - newser.com
Traws Pharma, Inc. (TRAW) stock price, news, quote and history - Yahoo Finance UK
Traws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline Advances - MyChesCo
How Traws Pharma Inc. (0T20) stock trades pre earningsWeekly Gains Summary & Long-Term Capital Growth Ideas - newser.com
Price action breakdown for Traws Pharma Inc.2025 Market Overview & Low Drawdown Momentum Ideas - newser.com
Traws Pharma Inc Stock (TRAW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):